NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Eli Lilly and Company
Conditions: Opioid Use Disorder
Interventions: Brenipatide, Placebo, Buprenorphine
Countries: United States, Canada, Puerto Rico, United Kingdom
The purpose of this study is to see if brenipatide, when compared to placebo, is safe and effective for participants with opioid use disorder, when used with buprenorphine with or without naloxone. The maximum potential duration of study participation for a participant in Part A is approximately 144 weeks, maximum potential duration of study participation for a participant in Part B is approximately 116 weeks. The actual duration will vary for each participant depending on the time of enrollment and the overall rate of study enrollment.
Sex: ALL
Age: 18 Years to 75 Years
Healthy volunteers: No
Study type: INTERVENTIONAL
Inclusion Criteria: * Have a current mild, moderate or severe opioid use disorder (OUD) * Are reliable and willing to make themselves available for the duration of the study (for example, are not incarcerated, not homeless) and attend required study visits, and are willing and able to follow study procedures as required, such as * self-inject study intervention Note: Participants who are not able to perform the injections must have the assistance of a support person trained to administer the study intervention * store and use the provided study intervention as directed * maintain electronic or paper study diaries, as applicable, and * complete the required questionnaires * Are intermittently using non-legal, non-prescribed opioids * Are taking buprenorphine for treatment on OUD Exclusion Criteria: * Evidence of other substance use disorder(s) within 180 days of screening, except the following are permitted: any level tobacco use disorder, mild-to-moderate alcohol or mild-to-moderate cannabis use disorder Note: any level of caffeine use is allowed * Are actively suicidal or deemed a significant risk for suicide * Have a history of advanced liver disease (including advanced liver fibrosis or cirrhosis or alcohol-associated hepatitis based on either prior liver histology or imaging studies, such as transient elastography, ultrasound, computed tomography (CT) and magnetic resonance imaging (MRI), or Enhanced Liver Fibrosis score * Have participated in a clinical study and received active treatment, or unknown if they received active treatment, within 90 days or 5 half-lives (whichever is longer) before screening * Had opioid overdose in past 6 months prior to screening * Have a lifetime history or current diagnosis of the following: * schizophrenia or other psychotic disorder * bipolar disorder * borderline personality disorder * any eating disorder * Have type 1 diabetes mellitus, or a history of ketoacidosis, or hyperosmolar state, or coma
- Phoenix, Arizona, United States
- Little Rock, Arkansas, United States
- Little Rock, Arkansas, United States
- Fountain Valley, California, United States
- San Francisco, California, United States
- San Francisco, California, United States
- Bradenton, Florida, United States
- Daytona Beach, Florida, United States
- Hollywood, Florida, United States
- Lakeland, Florida, United States
- Miami, Florida, United States
- Naples, Florida, United States
- Port Charlotte, Florida, United States
- Tampa, Florida, United States
- West Palm Beach, Florida, United States
- Chicago, Illinois, United States
- Indianapolis, Indiana, United States
- Lexington, Kentucky, United States
- Baltimore, Maryland, United States
- Rockville, Maryland, United States
- Boston, Massachusetts, United States
- Boston, Massachusetts, United States
- Boston, Massachusetts, United States
- Watertown, Massachusetts, United States
- Ridgeland, Mississippi, United States
- New York, New York, United States
- The Bronx, New York, United States
- Columbus, Ohio, United States
- Oklahoma City, Oklahoma, United States
- Philadelphia, Pennsylvania, United States
- + 28 more on CT.gov